Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Activating mutations in epidermal growth factor receptor (EGFR) are key drivers of non-small cell lung cancer (NSCLC).
• Tyrosine kinase inhibitors (TKIs) targeting EGFR have improved patient outcomes through targeted therapy.
• Therapy adaptation and acquired resistance mechanisms complicate EGFR-targeted treatments.

Purpose of the Study:

• To review the development and targeting of EGFR-TKIs.
• To examine TKI-induced cellular death, adaptation, resistance, and clinical failure.
• To propose novel therapeutic strategies based on EGFR quaternary structure.

Main Methods:

• Literature review of EGFR-TKI development and resistance mechanisms.
• Analysis of EGFR signaling networks and structural changes.
• Exploration of quaternary structure-based therapeutic approaches.

Main Results:

• EGFR mutations drive NSCLC, with TKIs showing efficacy but facing resistance.
• Complex signaling networks and adaptation mechanisms contribute to treatment failure.
• Understanding EGFR quaternary structure offers new avenues for overcoming resistance.

Conclusions:

• Targeting EGFR mutations with TKIs has transformed NSCLC treatment but is limited by resistance.
• Novel strategies focusing on EGFR oligomerization and downstream signaling are needed.
• Exploiting EGFR quaternary structure holds promise for overcoming acquired resistance and improving patient survival.